The long-term objective of this proposal is to apply a powerful """"""""covalent tethering"""""""" technology to discover novel therapeutics for the treatment of type 2 diabetes. Protein tyrosine phosphatase-1B (PTP-1B) has emerged as a compelling target for treating diabetes, but it has been difficult to identify cell permeable, drug-like inhibitors of this important enzyme. Covalent tethering technology involves discovering drug-like fragments that bind to a target protein and assembling them into potent inhibitors. Cysteine mutations are introduced to target a site of interest and a collection of disulfide-containing fragments are screened to identify compounds that bind and form a disulfide bond. Compared to traditional screening, a greater chemical diversity is surveyed by identifying the individual components of binding and subsequently combining them into a common molecule. We propose to use covalent tethering and structure-based design to target two adjacent binding sites on PTP-1B. We will first identify pharmaceutically desirable phophotyrosine mimetics for the conserved active site and then identify fragments that bind to a unique, nearby site. These fragments will be merged into a bimodal inhibitor that combines potency and specificity to overcome problems observed with existing inhibitors. Covalent tethering is ideally suited to identifying such bimodal molecules. ? ?
| Shiau, Timothy P; Erlanson, Daniel A; Gordon, Eric M (2006) Selective reduction of peptide isothiazolidin-3-ones. Org Lett 8:5697-9 |
| Hansen, Stig K; Cancilla, Mark T; Shiau, Timothy P et al. (2005) Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue. Biochemistry 44:7704-12 |
| Wiesmann, Christian; Barr, Kenneth J; Kung, Jenny et al. (2004) Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 11:730-7 |
